BioWa, Inc.

24.05.2005 – 17:26
BioWa and Medarex Announce Expansion of Licensing Agreement for BioWa's Potelligent(TM) Technology
Princeton, New Jersey (ots/PRNewswire) - - BioWa Grants the Second Potelligent(TM) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent(TM) Technology for the enhancement of ...
mehr
23.03.2005 – 01:49
BioWa, Inc. Licenses Anti IL-5 Receptor Antibody from Kyowa Hakko Kogyo Co., Ltd.
Princeton, New Jersey (ots/PRNewswire) - BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment. Under the terms of the ...
mehr